| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee2b0256bf53495400ed438da3da663c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6467
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21079
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_268214ab97732d6a81405653273c8aa6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a056c1ef12916cf136e4800c0952960b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf25f0a1ae6dbfe3535567af6b7865d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4819710ad87787c3fc6a11808d10d325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90f0dd6c58c3a320b1a5a5fceec8a418 |
| publicationDate |
2020-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3725322-A1 |
| titleOfInvention |
Oncolytic adenoviral vector expressing granzyme and perforin |
| abstract |
The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing granzyme and perforin in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject. |
| priorityDate |
2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |